|
1
|
Hu K, Ding P, Wu Y, Tian W, Pan T and
Zhang S: Global patterns and trends in the breast cancer incidence
and mortality according to sociodemographic indices: An
observational study based on the global burden of diseases. BMJ
Open. 9(e028461)2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ali ANM and Muslim SN: Breast cancer in
Iraq: A comprehensive review of disease burden, risk factors, and
healthcare response. South Asian Res J Bio Appl Biosci. 7:349–360.
2025.
|
|
3
|
Al-Hashimi MMY: Trends in breast cancer
incidence in Iraq during the period 2000-2019. Asian Pac J Cancer
Prev. 22:3889–3896. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mutar MT, Goyani MS, Had AM and Mahmood
AS: Pattern of presentation of patients with breast cancer in Iraq
in 2018: A cross-sectional study. J Glob Oncol. 5:1–6.
2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shackleton M, Quintana E, Fearon ER and
Morrison SJ: Heterogeneity in cancer: Cancer stem cells versus
clonal evolution. Cell. 138:822–829. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sottoriva A, Verhoeff JJC, Borovski T,
McWeeney SK, Naumov L, Medema JP, Sloot PM and Vermeulen L: Cancer
stem cell tumor model reveals invasive morphology and increased
phenotypical heterogeneity. Cancer Res. 70:46–56. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mohan A, Raj Rajan R, Mohan G, Kollenchery
Puthenveettil P and Maliekal TT: Markers and Reporters to Reveal
the Hierarchy in Heterogeneous Cancer Stem Cells. Front Cell Dev
Biol. 9(668851)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Keller L, Werner S and Pantel K: Biology
and clinical relevance of EpCAM. Cell Stress. 3(165)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barzegar Behrooz A, Syahir A and Ahmad S:
CD133: Beyond a cancer stem cell biomarker. J Drug Target.
27:257–269. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Batlle E and Clevers H: Cancer stem cells
revisited. Nat Med. 23:1124–1134. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
11
|
Glumac PM and LeBeau AM: The role of CD133
in cancer: A concise review. Clin Transl Med. 7(18)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Joseph C, Arshad M, Kurozomi S, Althobiti
M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG,
et al: Overexpression of the cancer stem cell marker CD133 confers
a poor prognosis in invasive breast cancer. Breast Cancer Res
Treat. 174:387–399. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vasiliou V, Pappa A and Petersen DR: Role
of aldehyde dehydrogenases in endogenous and xenobiotic metabolism.
Chem Biol Interact. 129:1–19. 2000.PubMed/NCBI View Article : Google Scholar
|
|
14
|
WHO Classification of Tumours Editorial
Board: Breast tumours. Volume 2. 5th Edition. International Agency
for Research on Cancer, Lyon, 2019.
|
|
15
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC (eds), et al: AJCC cancer staging manual. 8th ed. New
York, Springer, 2017.
|
|
16
|
Ahmed NAES and Mohammed MH: Significance
of CD133 expression in invasive ductal carcinoma of the breast.
Asian Pac J Cancer Biol. 7:9–14. 2022.
|
|
17
|
Han Z, Chen Z, Zheng R, Cheng Z, Gong X
and Wang D: Clinicopathological significance of CD133 and CD44
expression in infiltrating ductal carcinoma and their relationship
to angiogenesis. World J Surg Oncol. 13(56)2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu TT, Li XF, Wang L and Yang JL: CD133
expressionand clinicopathologic significance in benign and
malignant breast lesions. Cancer Biomark. 28:293–299.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wu L, Katsube T, Li X, Wang B and Xie Y:
Unveiling the impact of CD133 on cell cycle regulation in radio-
and chemo-resistance of cancer stem cells. Front Public Health.
13(1509675)2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li Z, Yin S, Zhang L, Liu W, Chen B and
Xing H: Clinicopathological characteristics and prognostic value of
cancer stem cell marker CD133 in breast cancer: A meta-analysis.
Onco Targets Ther. 10:859–870. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zwoliński M, Hovagimyan A, Smug W,
Szymankiewicz M, Lewandowski T, Bieniek A, Pawluczyk M, Szuleka M,
Puchowska A, Iwaniuk D, et al: Expression of CD133-stem cell marker
in colorectal cancer. Med Res J. 10:271–279. 2025.
|
|
22
|
Kim SJ, Kim YS, Jang ED, Seo KJ and Kim
JS: Prognostic impact and clinicopathological correlation of CD133
and ALDH1 expression in invasive breast cancer. J Breast Cancer.
18:347–355. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yang F, Cao L, Sun Z, Jin J, Fang H, Zhang
W and Guan X: Evaluation of breast cancer stem cells and intratumor
stemness heterogeneity in triple-negative breast cancer as
prognostic factors. Int J Biol Sci. 12:1568–1577. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Moustafa ME, Fakhoury RM, Mahmood NA and
Yaseen NY: OCT3/4, ALDH-1 and CD44 expression levels in Iraqi women
with stage II-III breast cancer. J Med Biol Sci Res. 1:13–23.
2015.
|
|
25
|
Ma F, Li H, Li Y, Ding X, Wang H, Fan Y,
Lin C, Qian H and Xu B: Aldehyde dehydrogenase 1 (ALDH1) expression
is an independent prognostic factor in triple negative breast
cancer (TNBC). Medicine (Baltimore). 96(e6561)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gyan E, Green A, Ahenkorah-Fondjo L,
Jackson A, Toss MS, Akakpo PK, Derkyi-Kwarteng L, Rahman GA and
Owiredu W: The role of ALDH1A1 in contributing to breast tumour
aggressiveness: A study conducted in an African population. Ann
Diagn Pathol. 51(151696)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu JF, Xia P, Hu WQ, Wang D and Xu XY:
Aldehyde dehydrogenase 1 expression correlates with
clinicopathologic features of patients with breast cancer: a
meta-analysis. Int J Clin Exp Med. 8:8425–8432. 2015.PubMed/NCBI
|
